HHC exists in trace quantities in Cannabis sativa pollen and seeds, making it a minor phytocannabinoid. It was first synthesised in 1944 by American chemist Roger Adams, who used a catalytic hydrogenation process to convert THC into HHC , the same general chemistry used commercially to harden vegetable oils into margarine. Because natural concentrations are so low, any HHC encountered in consumer contexts is almost exclusively semi-synthetic, derived from cannabidiol (CBD) or THC via hydrogenation.
The hydrogenation process yields two main stereoisomers: (9R)-HHC and (9S)-HHC. Preliminary in-vitro binding studies suggest the 9R epimer has meaningfully higher affinity for CB1 receptors than the 9S form, though commercial preparations typically contain a mixture of both. The ratio of those epimers, and therefore the overall receptor-binding profile of any given sample, varies depending on the synthesis method used.
Research into HHC is at an early stage. As of 2024, peer-reviewed pharmacological data in humans is essentially absent; most available information comes from in-vitro receptor-binding assays and rodent models. Because HHC's chemical structure diverges from delta-9-THC, its behaviour under standard cannabinoid immunoassays is inconsistent, a point noted in several forensic chemistry reports. Its metabolic pathways in humans have not been fully characterised.
Under Australian law, HHC is not separately scheduled by name in the Poisons Standard (SUSMP), but it is widely considered to fall within the scheduling entry for THC analogues or under the broad definition of cannabinoids subject to TGA oversight. Synthetic and semi-synthetic cannabinoids occupy a complex regulatory space in Australia; supply without TGA approval can constitute a criminal offence under the Therapeutic Goods Act 1989 (Cth). Anyone seeking clarity on the regulatory status of a specific compound should consult the current Poisons Standard directly.
Sources: